Compare · STEM vs TMO
STEM vs TMO
Side-by-side comparison of Stem Inc. (STEM) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- STEM operates in Miscellaneous, while TMO operates in Industrials - the two are in different parts of the market.
- TMO is the larger of the two at $217.52B, about 3830.4x STEM ($56.8M).
- Over the past year, STEM is down 57.5% and TMO is up 20.2% - TMO leads by 77.6 points.
- STEM has been more active in the news (16 items in the past 4 weeks vs 11 for TMO).
- Both have 25 recent analyst ratings on file.
- Company
- Stem Inc.
- Thermo Fisher Scientific Inc
- Price
- $6.33+0.96%
- $588.00-1.29%
- Market cap
- $56.8M
- $217.52B
- 1M return
- +1.20%
- +8.23%
- 1Y return
- -57.46%
- +20.18%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NYSE
- NYSE
- IPO
- 1992
- News (4w)
- 16
- 11
- Recent ratings
- 25
- 25
Stem Inc.
Stem, Inc. provides artificial intelligence (AI)-driven clean energy storage services. It delivers and operates smart battery storage solutions that maximize renewable energy generation and help build a resilient grid. The company's Athena, a AI-powered analytics platform software that uses artificial intelligence and machine learning to automatically switch between battery power, onsite generation, and grid power. Athena stabilizes the grid, reduces carbon emissions, and solves renewable intermittency across the network of distributed energy storage systems. The company serves customers, including Fortune 500 corporate energy users, project developers and installers, and utilities and independent power producers. Stem, Inc. was founded in 2009 and is headquartered in San Francisco, California.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest STEM
- SEC Form S-8 filed by Stem Inc.
- SEC Form 10-Q filed by Stem Inc.
- Stem Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Stem Announces Second Quarter 2026 Results
- Stem's PowerTrack EMS Enables Hybridization of Two Operating Utility-Scale Solar Plants in Hungary
- Director Shivram Krishna converted options into 7,486 shares, increasing direct ownership by 241% to 10,597 units (SEC Form 4)
- Director Buzby David S converted options into 7,486 shares (SEC Form 4)
- Director Daley Adam converted options into 7,486 shares, increasing direct ownership by 62% to 19,535 units (SEC Form 4)
- Director Tammineedi Anil converted options into 7,486 shares, increasing direct ownership by 94% to 15,473 units (SEC Form 4)
- Director Guruswamy Vasudevan converted options into 7,486 shares, increasing direct ownership by 241% to 10,597 units (SEC Form 4)
Latest TMO
- Executive Vice President Shafer Michael D exercised 25,500 shares at a strike of $370.58 and sold $15,300,000 worth of shares (25,500 units at $600.00) as part of a pre-agreed trading plan (SEC Form 4)
- Thermo Fisher Scientific Completes Sale of its Microbiology Business to Astorg
- VP & Chief Accounting Officer Holmes Joseph R. exercised 420 shares at a strike of $309.63 and sold $245,620 worth of shares (420 units at $584.81) (SEC Form 4)
- Chairman & CEO Casper Marc N exercised 275 shares at a strike of $309.63 and sold $2,862,002 worth of shares (4,883 units at $586.12) as part of a pre-agreed trading plan (SEC Form 4)
- Sr. VP and Chief HR Officer Britt Lisa P. exercised 5,850 shares at a strike of $309.63 and sold $3,393,000 worth of shares (5,850 units at $580.00), decreasing direct ownership by 0.00% to 14,784 units (SEC Form 4)
- Chairman & CEO Casper Marc N exercised 10,000 shares at a strike of $309.63 and sold $8,616,967 worth of shares (15,000 units at $574.46) as part of a pre-agreed trading plan, decreasing direct ownership by 0.00% to 123,925 units (SEC Form 4)
- Chairman & CEO Casper Marc N exercised 10,000 shares at a strike of $309.63 and sold $8,628,434 worth of shares (15,000 units at $575.23) as part of a pre-agreed trading plan, decreasing direct ownership by 0.00% to 123,925 units (SEC Form 4)
- SEC Form 10-Q filed by Thermo Fisher Scientific Inc
- President & COO Pettiti Gianluca sold $226,000 worth of shares (400 units at $565.00) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 24,651 units (SEC Form 4)
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits